Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for ...

Fibrosis of the lungs is often a silent disease until it's too late. By the time patients are diagnosed, the scarring of their lung tissue is already advanced, and current treatments offer little more ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...

Researchers at Baylor College of Medicine and collaborating institutions have uncovered a key molecular player that is involved in lung repair and in the development of pulmonary fibrosis, a common ...

Panelists discuss how managing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires a comprehensive, patient-centered approach that addresses not only physiological ...

The Pulmonary Fibrosis Foundation (PFF) today announced a new five-year strategic plan, The PFF is ME, a community-driven roadmap shaped by input from more than 350 people affected by pulmonary ...

CLEVELAND, Ohio — Many patients with advanced cystic fibrosis — an illness that causes thick mucus secretions — turn to lung transplants to improve their quality of life. But in taking that step, they ...

Cystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, ...